Madri­gal touts a mid-stage suc­cess in HeFH, cut­ting bad cho­les­terol in a com­pet­i­tive field

Madri­gal Phar­ma­ceu­ti­cals $MDGL is tout­ing a batch of pos­i­tive mid-stage da­ta from their 12-week LDL/C-low­er­ing tri­al in treat­ment-re­sis­tant pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HeFH), an in­tense­ly com­pet­i­tive field with a ros­ter of play­ers look­ing to make their mark.

In the study, in­ves­ti­ga­tors say that an “op­ti­mal” dose of MGL-3196 spurred cuts of 18.8% and 21%. The com­pa­ny adds:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER